Pharmaceutical Executive

🎉 It's official: the future of pharma is in very good hands. Meet the winners of the 2026 Emerging Pharma Leader Awards. Here are five standout honorees selected for the vision, drive & impact they bring to the industry. These are the names shaping pharma's next chapter & this recognition is well earned. Congratulations to Sarah Ghosh, MBA, Nick Botwood, Rena Nassr Denoncourt, Christopher Savage, & Abid Rahman on this great achievement! A big thank you to BGBx for sponsoring this year's awards. 👏 Join us in the comments in congratulating this year's honorees.

As AI reshapes how biopharma operates, the gap between companies with connected, structured data and those without keeps widening. Courier Health Founder and CEO Danny Sigurdson unpacks what it takes to harness AI and the role it plays in orchestrating more seamless patient experiences. Watch now: https://hubs.li/Q04rSwRR0 #PatientExperience #AIinPharma

Physicians are leaving clinical practice roughly nine years earlier than a generation ago. A national survey published in The Permanente Journal, drawn from nearly 1,000 clinically inactive doctors who completed residency between 2000 and 2022, found the mean age at departure is now 48.1, down from 57.1 in a comparable 2008 cohort. It's the clearest look in more than a decade at why doctors are stepping away early, and what may be driving the next wave of burnout. Read more: https://hubs.li/Q04rDKzT0 #PhysicianBurnout #Healthcare

The next competitive advantage in healthcare may already be sitting in plain sight: stronger patient and HCP engagement. Reverba Global's Content Engagement Hub on https://hubs.li/Q04q_1-Z0 features expert insights, practical frameworks, and real-world examples that show how connected engagement strategies can optimize the patient experience while strengthening relationships with healthcare professionals from clinical development through commercialization. Access the Hub: https://hubs.li/Q04q-ZT-0 #ScientificEngagement #PatientEngagement #HCPEngagement #PatientExperience #MedicalAffairs #ClinicalTrials #OmnichannelMarketing #Pharma #Biotech #PharmExec

Real-world data is reshaping clinical trials, but the richest insights are often buried in unstructured clinical notes. Join Verana Health for a webinar exploring how AI is unlocking that data to improve trial design, accelerate patient identification, and understand long-term treatment outcomes. Featuring new research from the Tufts Center for the Study of Drug Development. Register now:https://hubs.li/Q04qH9NJ0

The calls. The quotes. The perspectives shaping pharma's biggest conversations before they hit the headlines. Michael Hollan, Managing Editor of Pharmaceutical Executive, sits down on Exec on Execs to unpack what industry leaders are actually saying. If you're not tuning in, you're missing where the industry's thinking is headed. Watch the latest episode below. 🎥 #Pharma #ExecOnExecs #PharmExec #Leadership #PharmaLeadership

China's rise in biotech isn't a surprise. It was a deliberate, decades-long strategy. John Stanford, Executive Director at Incubate, argues that the surge in Chinese biotech licensing is the direct result of sustained investment modeled on the same Bayh-Dole Act and NIH funding framework that gave the U.S. four decades of biomedical leadership. China followed that playbook consistently, and the results are now visible in $43 billion in licensing deals in the first five months of 2026 alone. Stanford makes the case that the U.S. response shouldn't be to restrict those deals, but to remove the barriers slowing domestic biotech investment down. Read the full Q&A in the comments 👇 #Pharma #Biotech #ChinaBiotech #BiotechPolicy #PharmExec

New feature on Inizio Engage's end-to-end patient support model, presented by Jason Rains (SVP, Patient Access) and Randy Quist (VP, Field Reimbursement). Built on 25 years of nurse clinical education experience, the approach uses a non-dispensing pharmacy to streamline the front end of treatment, with smart automation guiding patients through benefits investigation and prior authorization. Watch Now: https://hubs.li/Q04q8h5F0 #PharmaceuticalExecutive #PatientAccess #SpecialtyPharmacy

Chinese biotech isn't just catching up. It's competing on innovation. $43 billion in licensing agreements with Chinese companies was announced in just the first five months of 2026. John Stanford, Executive Director at Incubate, explains why: two decades of deliberate investment, modeled on the same Bayh-Dole and NIH playbook that gave the U.S. four decades of biomedical leadership, is now paying off. And the U.S. government is taking notice, with a bipartisan push to add biotech to the Treasury's outbound investment screening list. Watch the short below and find the full interview in the comments. 🎥 #Pharma #Biotech #ChinaBiotech #NationalSecurity #PharmExec

Project TrialBlazer aims to cut clinical trial timelines by six to twelve months. But is it solving the right problem? Dr. Richard Graham, chairman and co-founder of TruTechnologies, says the initiative is directionally correct but argues that the companies he works with are already defaulting to Australia for Phase 1 studies, where the equivalent of no IND is required at all. Once that behavior sets in, regulatory reform alone may not be enough to reverse it. Watch the short below and find the full interview in the comments. 🎥 #Pharma #ClinicalTrials #ProjectTrialBlazer #DrugDevelopment #PharmExec